Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Newchem S P A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner. The prosecution is localized within 1 distinct art unit, reflecting a specific technical focus for the company's current patent activity. The involvement of 1 distinct examiner and 1 distinct art unit suggests a centralized interaction with the patent office at this time.
The busiest examiner for the company is CHENG, KAREN, who is responsible for 1 busiest examiner pending action. This single action represents the entire pending workload for the portfolio. With 1 distinct examiner and 1 distinct art unit, the company's current interaction with the patent office is concentrated under a single reviewer. Practitioners should recognize that the prosecution of this Biotechnology & Pharmaceuticals portfolio is currently dependent on the findings of CHENG, KAREN.
The presence of 1 pending office action and 1 distinct examiner suggests that the company's immediate patent strategy is focused on a single application or a very closely related set of claims. For a patent practitioner, this means that the outcome of the current pending matter is tied to a single individual's review and a single art unit's standards. Any developments in this 1 pending office action will define the company's current progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHENG, KAREN | 1 | 76.4% | +26.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580851 | PROCESSES FOR THE PREPARATION OF ESTETROL AND INTERMEDIATES THEREOF | CHENG, KAREN | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580851 | PROCESSES FOR THE PREPARATION OF ESTETROL AND INTERMEDIATES THEREOF | CHENG, KAREN | 1623 | §112 | Non-Final OA | — | Pending | Jan 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNewchem S P A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karen Cheng has the most, with 1 of Newchem S P A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
